Effects of Fengbaisan on the expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung tissue of rats with chronic obstructive pulmonary disease

Chinese Journal of Integrative Medicine

Volumn 20, Issue 3, 2014, Pages 224-231

  Wang, Yu ^a,b   Su, Nan Xiang ^a   Chen, Ze Qi ^b   Wang, Zhe ^a   Zhang, Si Fang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

airway remodeling; Chinese medicine; chronic obstructive pulmonary disease; Fengbaisan; matrix metalloproteinase 9; tissue inhibitor of metalloproteinase 1

Indexed keywords

AMBROXOL; CHINESE DRUG; CIGARETTE SMOKE; EOSIN; FENGBAISAN; GELATINASE B; HEMATOXYLIN; LIPOPOLYSACCHARIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUNG PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MATRIX METALLOPROTEINASE 9; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, WISTAR; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84896518346     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-013-1619-z     Document Type: Article

References (60)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-1243. (Pubitemid 28512100)
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555. (Pubitemid 47403272)
3. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-688. (Pubitemid 37258549)
4. Belvisi MG, Bottomley KM. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm Res 2003;52:95-100. (Pubitemid 36470068)
5. Su NX, Zhang SF, He MD. Observe the clinical efficacy of Fengbaisan on patients with chronic bronchitis. J Chin Phys (Chin) 2003;5:1134-1135.
6. Su NX, Liu SM, Ge XP, Zhang SF, He MD. The effects of Fengbaisan on the level of TNF-α, IL-2 in peripheral blood of patients with chronic bronchitis. J Tradit Chin Med Univ Hunan (Chin) 2005;25:35-37.
7. Pan SG, Su NX, Wang Z, Zhang SF, Wang Y. Effect of Fengbaisan Decoction on expression of γ-GCS and SOD in rats with chronic obstructive pulmonary disease. J Tradit Chin Med Univ Hunan (Chin) 2009;29:36-39.
8. The Ministry of Science and Technology of the People's Republic of China. Guidance suggestions for the care and use of laboratory animals. 2006;9-30.
9. Song YP, Cui DJ, Mao PY, Liang YJ, Wang DW. A study on pathological changes and the potential role of growth factors in the airway wall remodeling of COPD rat models. Chin J Tubercul Respir Dis (Chin) 2001;24:283-287.
10. Shannon RS, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-661. (Pubitemid 351348146)
11. Ren YC, Wang L, He HB, Tang X. Pulmonary selectivity and local pharmacokinetics of ambroxol hydrochloride dry powder inhalation in rat. J Pharm Sci 2009;98:1797-1803.
12. Li YQ, Zhang ZX, Xu YJ, Ni W, Cheng SX, Ma D, et al. Effects of cigarette smoke medium on activity of alveolar macrophages and expression of MMP-9 and TIMP-1 in COPD rats. Chin J Tubercul Respir Dis (Chin) 2005;28:648-649.
13. Pelkonen M. Smoking: relationship to chronic bronchitis, chronic obstructive pulmonary disease and mortality. Curr Opin Pulm Med 2008;14:105-109. (Pubitemid 351323160)
14. Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985;64:111-126. (Pubitemid 16135783)
15. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLB/WHO Global Initiative for Chronic Obstructive Lung Disease (COLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276. (Pubitemid 32378468)
16. Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest 1999;115:829-835. (Pubitemid 29129968)
17. Rylander R. Endotoxin in the environment - exposure and effects. J Endotoxin Res 2002;8:241-252.
18. Larsson L, Szponar B, Pehrson C. Tobacco smoking increases dramatically air concentrations of endotoxin. Indoor Air 2004;14:421-424. (Pubitemid 39523854)
19. Larsson L, Szponar B, Ridha B, Pehrson C, Dutkiewicz J, Krysinska-Traczyk E, et al. Identification of bacterial and fungal components in tobacco and tobacco smoke. Tob Induc Dis 2008;4:4.
20. Sebastian A, Pehrson C, Larsson L. Elevated concentrations of endotoxin in indoor air due to cigarette smoking. J Environ Monit 2006;8:519-522.
21. Rushton L. Occupational causes of chronic obstructive pulmonary disease. Rev Environ Health 2007;22:195-212. (Pubitemid 350072273)
22. Sarir H, Henricks PA, van Houwelingen AH, Nijkamp FP, Folkerts G. Cells, mediators and Toll-like receptors in COPD. Eur J Pharmacol 2008;585:346-353.
23. George CL, Jin H, Wohlford-Lenane CL, O'Neill ME, Phipps JC, O'Shaughnessy P, et al. Endotoxin responsiveness and subchronic grain dust-induced airway disease. Am J Physiol Lung Cell Mol Physiol 2001;280:L203-L213.
24. Vogelzang PF, van der Gulden JW, Folgering H, Kolk JJ, Heederik D, Preller L, et al. Endotoxin exposure as a major determinant of lung function decline in pig farmers. Am J Respir Crit Care Med 1998;157:15-18. (Pubitemid 28071255)
25. Wright JL, Postma DS, Kerstjens HA, Timens W, Whittaker P, Churg A. Airway remodeling in the smoke exposed guinea pig model. Inhal Toxicol 2007;19:915-923. (Pubitemid 350112226)
26. Churg A, Wang R, Wang XS, Onnervik PO, Thim K, Wright JL. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodeling in guinea pigs. Thorax 2007;62:706-713. (Pubitemid 47235016)
27. Toward TJ, Broadley KJ. Goblet cell hyperplasia, airway function, and leukocyte infiltration after chronic lipopolysaccharide exposure in conscious Guinea pigs: effects of rolipram and dexamethasone. J Pharmacol Exp Ther 2002;302:814-821. (Pubitemid 34787252)
28. Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 2002;26:152-159. (Pubitemid 34029832)
29. Brass DM, Savov JD, Gavett SH, Haykal-Coates N, Schwartz DA. Subchronic endotoxin inhalation causes persistent airway disease. Am J Physiol Lung Cell Mol Physiol 2003;285:L755-L761. (Pubitemid 37022877)
30. Kaneko Y, Takashima K, Suzuki N, Yamana K. Effects of theophylline on chronic inflammatory lung injury induced by LPS exposure in guinea pigs. Allergol Int 2007;56:445-456. (Pubitemid 350306398)
31. Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:478-485. (Pubitemid 351669174)
32. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008;8:183-192. (Pubitemid 351323287)
33. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008;31:1334-1356.
34. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011;365:1567-1575.
35. van den Berge M, ten Hacken NH, Cohen J, Douma WR, Postma DS. Small airway disease in asthma and COPD: clinical implications. Chest 2011;139:412-423.
36. Hogg JC, Chu F, Utokaparach S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653. (Pubitemid 38787999)
37. Sturton G, Persson C, Barnes PJ. Small airways: an important but neglected target in the treatment of obstructive airway diseases. Tr Pharmacol Sci 2008;29:340-345.
38. Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 2001;2:10-19. (Pubitemid 34187902)
39. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996;156:1-4. (Pubitemid 26006939)
40. Kelly EA, Busse WW, Jarjour NN. Increased matrix metalloproteinase-9 in the airway after allergen challenge. Am J Respir Crit Care Med 2000;162:1157-1161.
41. Kheradmand F, Rishi K, Werb Z. Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2. J Cell Sci 2002;115:839-848. (Pubitemid 34196343)
42. Mautino G, Oliver N, Chanez P, Bousquet J, Capony F. Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol 1997;17:583-591. (Pubitemid 127499061)
43. Wojtowicz-Praga SM, Dickson RB, and Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75. (Pubitemid 27217752)
44. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 1993;59:329-341. (Pubitemid 23344435)
45. Shapiro SD. Elastolytic metalloproteinases produced by human mononuclear phagocytes: potential roles in destructive lung disease. Am J Respir Crit Care Med 1994;150:S160-S164. (Pubitemid 24364342)
46. Betsuyaku T, Nishimura M, Takeyabu K, Tanino M, Venge P, Xu SY, et al. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med 1999;159:1985-1991. (Pubitemid 29275073)
47. Finlay GA, Russell KJ, McMahon KJ, D'Arcy EM, Masterson JB, FitzGerald MX, et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997;52:502-506. (Pubitemid 27298499)
48. Omachi TA, Eisner MD, Rames A, Markovtsova L, Blanc PD. Matrix metalloproteinase-9 predicts pulmonary status declines in a1-antitrypsin deficiency. Respir Res 2011;12:35-45.
49. Vignola AM, Riccobono L, Mirabella A, Profita M, Chanez P, Bellia V, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998;158:1945-1950. (Pubitemid 29008837)
50. Culpitt SV, Rogers DF, Traves SL, Barnes PJ, Donnelly LE. Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005;99:703-710. (Pubitemid 40631296)
51. Vernooy JH, Lindeman JH, Jacobs JA, Hanemaaijer R, Wouters EF. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004;126:1802-1810. (Pubitemid 39643983)
52. Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003;97:634-639. (Pubitemid 36675664)
53. Yue YY, Li YC. Protective effect of salvia injection on the airway in rats with COPD. Clin Rational Drug Use (Chin) 2011;4:15-17.
54. Huang DH. Effect of danshen injection on transforming growth factor-β1 in COPD airway remodelling rats. Chin J Inform Tradit Chin Med (Chin) 2008;15:36-38.
55. Zhao Y. Effect of complex Salvia miltiorrhiza on the changes of pulmonary function and HMGB1 in the serum of COPD patients. J Modern Med Health (Chin) 2008;24:2891-2893.
56. Yuan WS, Sun JM. The effects of Slavia miltiorrhiza injection on the expression of sICAM-1 of patients with COPD. Chin J Rehabilit (Chin) 2009;24:250-252.
57. Zhao J, Liu ZQ, Luo AG, Ai H, Song JJ, Zhao JL, et al. Influence of Astragalus polysaccharide on hydroxyproline and MMP-9 in rats with COPD. J Beijing Univ Tradit Chin Med (Chin) 2009;32:759-762.
58. Yu WW, Huang XY, Zhang Y, Xia Q. Effect of Astragalus polysaccharide on the expression of MMP-9 and TIMP-1 in lung tissue of COPD rats. Chin Med Herald (Chin) 2012;9:25-27.
59. Liu L. Influence of astragalus injection on pulmonary function and immune function in chronic obstructive pulmonary disease. Chin Modern Doc (Chin) 2010;48:3-4.
60. Chen SQ, Li W. Curative effects of milkvetch root injections in acute chronic obstructive pulmonary disease and immunically functional effects of lymphocyte. Chin Modern Doc (Chin) 2008;46:40-41.